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OBJECTIVE — Newermedicationsoffermoreoptionsforglycemiccontrolintype2diabetes.
However, they come at considerable costs. We undertook a health economic analysis to better
understandthevalueofaddingtwonewermedications(exenatideandsitagliptin)assecond-line
therapy to glycemic control strategies for patients with new-onset diabetes.
RESEARCH DESIGN AND METHODS — We performed a cost-effectiveness analysis
for the U.S. population aged 25–64. A lifetime analytic horizon and health care system perspec-
tive were used. Costs and quality-adjusted life years (QALYs) were discounted at 3% annually,
and costs are presented in 2008 U.S. dollars. We compared three glycemic control strategies: 1)
glyburide as a second-line agent, 2) exenatide as a second-line agent, and 3) sitagliptin as a
second-line agent. Outcome measures included QALYs gained, incremental costs, and the in-
cremental cost-effectiveness ratio associated with each strategy.
RESULTS — Exenatide and sitagliptin conferred 0.09 and 0.12 additional QALYs, respec-
tively, relative to glyburide as second-line therapy. In base case analysis, exenatide was domi-
nated (cost more and provided fewer QALYs than the next most expensive option), and
sitagliptin was associated with an incremental cost-effectiveness ratio of $169,572 per QALY
saved. Results were sensitive to assumptions regarding medication costs, side effect duration,
and side effect–associated disutilities.
CONCLUSIONS — Exenatide and sitagliptin may confer substantial costs to health care
systems. Demonstrated gains in quality and/or quantity of life are necessary for these agents to
provide economic value to patients and health care systems.
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D
iabetes is increasingly endemic in
the U.S. In 2007, 23.5 million
Americans aged 20 years had di-
abetes compared with 18.0 million in
2002 (1). Diabetes was the seventh lead-
ing cause of death in 2006 (1). It remains
the leading cause of blindness, end-stage
renal disease, and nontraumatic amputa-
tions. A total of $116 billion in direct
health care costs are attributable to diabe-
tes annually (2).
Large clinical trials from the U.S. and
Europe have demonstrated that tighter
glycemic control can prevent diabetes
complications in individuals with recent-
onset disease (3,4); in older individuals
with longer disease duration, recent stud-
ies have found no cardiovascular beneﬁt
of tight control (5) and possible harm (6).
In the past several years, the U.S. Food
and Drug Administration (FDA) ap-
proved nine new products for glycemic
control (7). Some are new forms or com-
binations of existing classes, whereas oth-
ersbelongtonewtherapeuticclassessuch
as amylin analogs, glucagon-like pep-
tide-1 receptor agonists, incretins, and
dipeptidyl peptidase-IV inhibitors.
Although these agents increase the
managementoptionsavailable,theycome
atincreasedcosts(8).Previousanalysesof
the health economics of glycemic control
were published before the FDA approval
of many new agents (9–11). Recent stud-
ies have examined the cost-effectiveness
of exenatide or sitagliptin in European
populations,reﬂectingcostsandmanage-
ment appropriate for the modeled popu-
lationsbutnotnecessarilyreﬂectiveofthe
U.S. (12–14).
In this analysis, we estimate the costs
associated with two of the most prescribed
examples of these new medications: ex-
enatideandsitagliptin.Weprojectthegains
in health outcomes necessary to have these
newer medications pose good economic
value for patients with new-onset diabetes,
using the incremental cost-effectiveness ra-
tio as our metric.
RESEARCH DESIGN AND
METHODS— Our model is an exten-
sion of a previously published model
(11), using as its platform the published
model’s analytic algorithm but changing
treatment regimens and inputs, in keep-
ing with the newer medications being
considered. Adults enter the analysis at
diabetes diagnosis and progress through
the model until death or age 95. Only pa-
tients between the ages of 25 and 64 with
newly diagnosed diabetes are included. It
is assumed that there is a 10-year lag be-
tween diabetes onset and diagnosis.
Patients have an annual risk of diabe-
tes complications, modiﬁed by age, race,
and sex, time since diabetes onset, time
sincediagnosis,treatment,A1Cachieved,
smoking, hypertension, and/or concomi-
tant hypercholesterolemia. It is assumed
that hypertensive patients develop com-
plications more rapidly than nonhyper-
tensive patients and that glycemic control
has no impact on the progression of cor-
onary heart disease. Costs accrue due to
diabetes treatment and treatment of dia-
betes complications. Costs are averted
when complications are averted (15).
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the value of exenatide and sitagliptin is
the incremental cost-effectiveness ratio
(ICER). In this analysis, ICER  (costs of
treatment–averted diabetes complica-
tion-related costs)/(quality-adjusted life
years [QALYs] gained). Costs were calcu-
lated from a health care system perspec-
tive,usingalifetimeanalytichorizon.Key
model assumptions are summarized in
Tables 1 and 2.
Treatment strategies
We assumed that intensive glycemic con-
trolisnowthestandardofcareintheU.S.
Three intensive glycemic control strate-
gies were modeled: 1) glyburide as sec-
ond-line treatment strategy, 2) exenatide
as second-line treatment strategy, and 3)
sitagliptin as second-line treatment strat-
egy. In each strategy, patients were
treated with combinations of metformin,
the second-line agent speciﬁc to the strat-
egy, rosiglitazone, and NPH insulin.
In all three strategies, patients requir-
ing medication were given metformin
initially. If glycemic control was not
achieved with metformin alone, other
medications were added, based on mod-
eledratesoftreatmentfailure(seesupple-
mentary Table, available in an online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-1488/DC1). All
three strategies incorporated rosiglita-
zone as third-line therapy.
Risks of diabetes complications
The methods used to estimate the proba-
bilities of diabetes complications have
been described elsewhere (15). In brief,
probabilities depended on time since di-
agnosis, time between onset and diag-
nosis, age, sex, race, glycemic levels,
smoking, cholesterol levels, and hyper-
tension (Table 1). Time since diagnosis,
glycemic level, and hypertension affected
all transition probabilities. Time between
onset and diagnosis affected the glycemic
level at the time of diagnosis. Age, sex,
smoking, and cholesterol level affected
transition probabilities associated with
coronary heart disease (CHD) and stroke.
Race affected glycemic levels and mortal-
ity. Alternative treatment strategies af-
fected transition probabilities by altering
a patient’s modeled trajectory of A1C lev-
els over time.
Glycemic control
All three strategies were assumed to pro-
vide the same degree of glycemic control
and, hence, the same effects on risks of
diabetes complications. This assumption
was based on results from clinical trials of
sitagliptin and exenatide (16–21).
Medication side effects
Health outcomes differed on the basis of
side effect proﬁles. Side effect proﬁles
Table 1—Assumptions regarding model parameters
Value Reference
Diabetes-related parameters
Interval between onset of diabetes and diagnosis (years) 10 15
Average hemoglobin A1C at time of diagnosis (%) 6.80 15
Treatment impact on A1C (%) 2.90 15
Rate of change in A1C, on treatment (%) 0.20 15
Hazard rates
Normal to microalbuminuria 0.02371
Microalbuminuria to nephropathy 0.06561
Normal to peripheral neuropathy 0.0294
Normal to photocoagulation 0.0079
Side effect–related parameters
Probability of weight gain while on glyburide (ﬁrst 2 years) (%) 100 33
Probability of weight loss while on exenatide (ﬁrst 2 years) (%) 100 33
Probability of hypoglycemia (%)
Glyburide 36.10 12
Sitagliptin 6.20 12
Exenatide 16.00 34
Probability of nausea/other gastrointestinal side effects while
taking glyburide (%) 4.20 19
Probability of nausea/other gastrointestinal side effects while
taking exenatide (%) 57.00 13
Probability of upper respiratory infection while on sitagliptin (%) 3.50 19
Costs per day ($)
Metformin, 2,000 mg 1.42 WSP, 35
Glyburide, 7.5 mg 0.42 WSP, 35
Sitagliptin, 100 mg 6.06 WSP, 35
Exenatide, 20 g 8.37 WSP, 35
Rosiglitazone, 8 mg 5.59 WSP, 35
NPH insulin, 10 units 0.90 WSP, 35
Injection-related supplies 0.52 WSP, 35
Annual utilities following
Blindness 0.69 15
Stroke 0.5 15
End-stage renal disease 0.61 15
Lower extremity amputation 0.8 15
WSP, wholesale price.
Table 2—Side effect–related quality-of-life assumptions
Side effect Glyburide Exenatide Sitagliptin Reference
Weight gain/loss 0.0031 0.0013 0 33
Hypoglycemia 0.0064 0.0005 0.0002 12,34,36
Nausea/gastrointestinal side effects 0 0.0005 0 Authors’ assumption;
13,33
Upper respiratory infections 0 0 0.0001 13
Injectable 0 0.0032 0 Authors’ assumption
Overall disutility associated with
side effects, after weighting* 0.0095 0.0029 0.0003
Apositivenumber(utility)indicatesagaininqualityoflife,andanegativenumber(disutility)indicatesaloss
in quality of life. *The overall disutility was calculated as the weighted sum of the side effect utilities/
disutilities, where the weights were 1) the probability a patient was on a given medication at a point in time
and 2) the probability the side effect occurred.
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line medications (glyburide, exenatide,
and sitagliptin) based on literature re-
view. Utilities (positive gains in quality of
life)ordisutilities(lossesinqualityoflife)
were applied to reﬂect these proﬁles. We
grouped these effects into ﬁve categories:
weight gain/loss, hypoglycemia, nausea/
othergastrointestinaleffects,upperrespi-
ratory infections, and the disutility
associatedwithaninjectableformulation.
Each side effect could be experienced by
the proportion of the population receiv-
ing a given drug at a given time. The ef-
fects of weight gain/loss, nausea and
upperrespiratoryinfectionwereassumed
to last for 2 years (13); all others were
assumed to last for the duration that the
medication was taken.
Glyburide was associated with a
weight gain of 3% experienced by all,
nausea experienced by 4.2%, and hypo-
glycemia experienced by 36.1%. Ex-
enatide was associated with a weight loss
of 5% (experienced by all), hypoglycemia
(experienced by 16%), nausea and other
gastrointestinal effects (experienced by
57%), and a disutility because it was an
injectable medication. Sitagliptin was as-
sociated with weight neutrality, hypogly-
cemia (experienced by 6.2%), and an
increased risk of minor upper respiratory
infections (experienced by 3.5%). All
three side effect proﬁles resulted in a net
disutility for each year the respective
medication was taken (Table 2).
Management of hypertension and
hypercholesterolemia
It was assumed that patients with hyper-
tension would receive antihypertensive
medicationsandthatpatientswithhyper-
cholesterolemia would be given statins.
The methods used were analogous to
those published previously (11).
Costs
All costs are presented in 2008 U.S. dol-
lars (Table 1). Both costs and health ben-
eﬁts were discounted at 3% annually and
estimated from the health care system
perspective. Costs of glycemic control in-
cluded the costs of the drugs themselves,
the costs of equipment needed for self-
injection of insulin, the costs of glucose
monitoring, and the costs of outpatient
careassociatedwithroutinefollow-upfor
diabetic patients. Costs of diabetes com-
plications were drawn from the same lit-
erature sources and used the same
methods of calculation as in the model
publishedpreviously(11).Thesecostsin-
cluded costs of procedures, inpatient and
outpatientcare,specialistvisits,andmed-
ications required for the management of
diabetic nephropathy, neuropathy, reti-
nopathy, CHD, and stroke.
Health beneﬁts
Prevention of diabetes complications re-
sults in a reduced risk of mortality and
improved quality of life. In the model,
strategies associated with improved gly-
cemic control reduced the transition
probabilities leading to diabetes compli-
cations at all stages, thereby reducing the
risks of death due to CHD, stroke, ne-
phropathy, or neuropathy. Retinopathy
was assumed to lead to blindness but not
to alter the risk of death.
Quality of life was captured by incor-
porating health utilities (Table 1) into the
model, where a utility of 1 describes a
period of time lived in perfect health and
a utility of 0 is assigned to death. Utility
values between 0 and 1 describe life lived
in less than perfect health and are used in
the calculation of QALYs (22). All analy-
ses were performed with custom software
built by the original study team (15).
RESULTS— All three strategies were
assumed to confer the same beneﬁts in
terms of reductions in major health out-
comes as a result of diabetes-related com-
plications.Theywereassumedtodifferin
their side effect proﬁles only, and these
sideeffectswerenotassumedtoalterrisks
of complications. The impacts of these
side effects were incorporated into the
model as quality-of-life gains or losses.
Use of sitagliptin as a second-line
treatment for type 2 diabetes in adults
65 years of age is associated with addi-
tional intervention costs of $20,213 per
person over a lifetime compared with a
baseline strategy using glyburide as sec-
ond-line therapy. Use of exenatide as a
second-line treatment is associated with
an additional cost of $23,849 over a
lifetime compared with glyburide as
second-line therapy. The differences in
intervention costs among the three strat-
egies were due to differences in medica-
tion costs, summarized in Fig. 1.
Incremental cost-effectiveness results
are summarized in Table 3. Changes in
costs and QALYs were calculated using
comparisons to the next most expensive
strategy, as well as to the common base-
line of the strategy incorporating gly-
buride as second-line therapy. The
strategy incorporating sitagliptin as sec-
ond-line therapy was associated with an
incremental cost-effectiveness ratio of
$169,572perQALYsaved,relativetogly-
buride as second-line therapy. Because
exenatide was 1) associated with an in-
jectable formulation with an accompany-
ing disutility and 2) had higher
medication-associated costs, the strategy
incorporating exenatide as second-line
therapy was dominated by that incorpo-
rating sitagliptin, meaning that it was
both more expensive and less effective in
terms of QALYs saved.
In one-way sensitivity analysis, when
thedisutilityassociatedwithaninjectable
medication was set to 0, exenatide ceased
to be dominated and was associated with
an incremental cost-effectiveness ratio of
$932,308 per QALY saved. In two-way
sensitivityanalysis,whenthedisutilityas-
sociated with an injectable medication
was set to zero and the medication cost of
exenatide was decreased by 25%, ex-
enatide exerted weak, also termed ex-
tended, dominance over sitagliptin and
was associated with a cost-effectiveness
ratio of $167,002 per QALY saved.
When utility gains and losses associ-
ated with weight changes were assumed
to last a lifetime, the incremental cost-
effectiveness ratio associated with sita-
gliptin was $141,833 per QALY saved. In
this analysis, exenatide ceased to be
dominated and was associated with an
incremental cost-effectiveness ratio of
$932,308 per QALY saved. In both the
analysisforwhichthedisutilityassociated
with injectable medication was negated
and in this lifetime weight change analy-
sis, the net disutility associated with ex-
enatide was 0, leading to similar results.
When incremental cost-effectiveness
analysis was performed using metformin
and glyburide with insulin as third-line
therapy (as opposed to rosiglitazone), ex-
enatide remained dominated and the
cost-effectiveness ratio associated with
sitagliptin changed minimally to
$173,300 per QALY saved. Finally, when
discount rates for costs and QALYs were
assumed to be 5%, the exenatide strategy
remained dominated, and the incremen-
tal cost-effectiveness ratio associated with
sitagliptinwas$154,389perQALYsaved.
CONCLUSIONS — Our results sug-
gestthatwidespreaduseofsitagliptinand
exenatideassecond-lineagentsinthegly-
cemic control of patients with diabetes
could be associated with $731 to $862
million additional direct health care costs
in the U.S. Additional quality-adjusted
life would be gained because of improved
Sinha and Associates
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drugs. These gains would cost roughly
$170 thousand per QALY for sitagliptin.
In the base case analysis, exenatide is
dominated, being both more costly and
generating fewer QALYs than sitagliptin.
A prior analysis of the cost-
effectiveness of glycemic control, based
on the UK Prospective Diabetes Study,
was published before FDA approval of
many new medications used in diabetes
management (11). Our model represents
an extension of this previously published
model, which has now been used to ad-
dress multiple diabetes-related policy
questions (11,23,24).
Previous analyses compared sitaglip-
tin and exenatide individually with ge-
neric drugs. Because the treatment
strategies used were different, countries
under analysis were different, and com-
parator strategies were different, direct
comparison of these analyses with the
current analysis are difﬁcult (12–14).
Importantly, this is the ﬁrst cost-
effectiveness analysis to compare ex-
enatide and sitagliptin to one another and
to glyburide for second-line therapy in a
single model. Because intensive glycemic
controlhasbecometheacceptedstandard
ofcareforhealthierindividuals65years
of age, our analysis focuses on alternative
strategies for achieving this goal (25). Di-
rectcomparisonofthisanalysistothepre-
vious analyses is complicated by the fact
that the current analysis is a comparison
of intensive control strategies alone. In
addition, unlike previous analyses, all
three strategies made use of a metformin-
ﬁrst approach, with rosiglitazone as a
third-line option and second-line therapy
varying by strategy. Finally, our analysis
incorporated hypertensive control and
statin therapy, as would be current stan-
dard practice.
Nonetheless,reviewofpreviousstud-
ies makes clear that the extent to which
nonglycemiccontroleffectsareattributed
to newer glycemic control agents inﬂu-
ences cost-effectiveness (12–14). For ex-
ample, exenatide use in the U.K., relative
tothatofinsulinglargine,wasfoundtobe
dominated by insulin glargine in one
study, whereas its use was found to be
cost-effective (with a cost-effectiveness
ratioof£22,420)inanother.Thesediffer-
ent results are explained by the former
model not attributing to exenatide im-
provementsinbloodpressureandinlipid
proﬁle (leading to improved cardiovascu-
lar outcomes), whereas the latter study
didmaketheseattributions.Becauseclin-
icaltrialsofexenatideandsitagliptinhave
not shown signiﬁcant differences in dia-
betes complication rates, including car-
diovascular events, we chose not to
ascribesuchbeneﬁtstoeithermedication.
Our ﬁndings suggest that the poten-
tial scale of health beneﬁts gained by use
Figure1—Dailytreatmentcosts.Over15years,theaveragedailytreatmentcostsfortheglyburide,sitagliptin,andexenatidestrategieswere$2.98,
$6.51, and $7.26, respectively.
Table 3—Results of cost-effectiveness analysis
Intensive control
treatment strategies
Cost of
medications Total costs
Incremental
costs QALYs
Incremental
QALYs
Incremental cost-
effectiveness ratio*
Cost-effectiveness ratio,
relative to glyburide strategy
Glyburide as second-line
therapy $65,205 $146,950 — 15.2143 — — —
Sitagliptin as second-line
therapy $85,418 $4,167,163 $20,213 15.3335 0.1192 $169,572 $169,572
Exenatide as second-line
therapy $89,054 $170,799 $3,636 15.2998 0.0337 Dominated $278,935
*Changes in costs in $ and QALYs were calculated relative to the next most expensive treatment strategy.
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of improved side-effect proﬁles, may be
substantial. Relative to glyburide as sec-
ond-line therapy, we found the use of ex-
enatide and sitagliptin to be associated
with an additional 0.09 and 0.12 QALYs
per patient. This result is comparable to
the scale of health beneﬁts provided by a
numberofhighlyeffectivepreventiveand
treatment strategies. For example, the use
of aspirin for secondary prevention of
myocardial infarction in 45-year-old men
has been estimated to provide a QALY
gain of 0.04 per patient (26). The use of
statinsinthesecondarypreventionofcor-
onary artery disease has been associated
withaQALYgainof0.25perpatient(27).
The use of 23-valent pneumococcal vac-
cine to prevent disease in elderly patients
has been associated with a QALY gain of
0.003 per patient (28).
We found results to be sensitive to
assumptions regarding medication cost,
incidence of medication effects, and dis-
utilities due to medication effects. Given
the impact that such effects have on pa-
tients’ daily lives and the importance of
these quality-of-life effects on cost-
effectiveness, further empirical study is
necessary to understand the preference-
weighted quality of life impact of these
effects, their costs, and their con-
sequences.
The American Diabetes Association
and European Diabetes have recently
published consensus guidelines for se-
quencing existing and new classes of
medications as initial therapies in diabe-
tes(29).Theserecommendationsarecon-
sistent with meta-analyses indicating that
antiglycemic oral agents and insulin used
to treat diabetes have comparable efﬁ-
cacy, (30,31), although they differ in
other effects and signiﬁcantly in costs.
Spending on antidiabetic agents nearly
doubled from 6.3% of all prescription
drug spending in 2004 to 12.3% in 2006,
and costs of treatment increased sharply
(9.5%) because of higher prices for non-
generic drugs and a shift in treatment mix
toward newer, more expensive products
(32).
Although side effects associated with
older medications may justify the use of
newer ones in individual cases, our study
suggeststhattheadditionalcostsofnewer
classes of drugs, when widely used in the
large U.S. diabetic patient population, re-
quirethatthevalueofthesedrugsbesup-
ported by substantial gains in health
outcomes to be recommended on a pop-
ulation basis. Better understanding of the
quality-of-life impacts of these drugs is
necessary to make such a case strongly.
For example, understanding the duration
of weight loss effects of some of these
medications and the potential down-
stream effects on macrovascular events
(coronary heart disease and stroke) could
contribute substantially to the value of
some of these medications.
Our study has several limitations. Re-
cently published long-term follow-up
studies of intensive glucose control have
demonstrated extended and improved
treatment beneﬁts, despite post-trial loss
of between-group glycemic differences
(4).Ourmodeldidnotintegratesuchleg-
acy effects, relying instead on a direct re-
lationship between glycemic control and
diabetes complications. If such legacy ef-
fects differ by medication class, then sig-
niﬁcant adjustment of the economic
modelwouldbenecessary.Themodelin-
corporates disutilities due to medication
effects, but does not yet account for costs
duetomanagementofsideeffectsormed-
ication switches that may occur due to
side effects.
Diabetes is an epidemic disease that
imposes substantial morbidity, prema-
ture mortality, and costs on the U.S. pop-
ulation. Appropriate treatment choices
are necessary to minimize the economic
burdenassociatedwiththisprevalentdis-
ease. Our study suggests that to provide
good economic value, newer medica-
tions, such as sitagliptin and exenatide,
need to confer health beneﬁts in scale
with the additional costs they bring to the
health care system.
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